Aratana Therapeutics Inc (NASDAQ:PETX) Shares Bought by Vanguard Group Inc

Vanguard Group Inc raised its holdings in Aratana Therapeutics Inc (NASDAQ:PETX) by 3.8% during the 3rd quarter, according to its most recent filing …

Aratana Therapeutics logoVanguard Group Inc raised its holdings in Aratana Therapeutics Inc (NASDAQ:PETX) by 3.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,044,208 shares of the biopharmaceutical company’s stock after acquiring an additional 75,166 shares during the quarter. Vanguard Group Inc owned approximately 4.20% of Aratana Therapeutics worth $11,938,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. BlackRock Inc. grew its position in Aratana Therapeutics by 2.7% in the 3rd quarter. BlackRock Inc. now owns 3,439,584 shares of the biopharmaceutical company’s stock valued at $20,087,000 after acquiring an additional 91,344 shares during the last quarter. Vanguard Group Inc. grew its position in Aratana Therapeutics by 3.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,044,208 shares of the biopharmaceutical company’s stock valued at $11,938,000 after acquiring an additional 75,166 shares during the last quarter. General American Investors Co. Inc. grew its position in Aratana Therapeutics by 15.9% in the 3rd quarter. General American Investors Co. Inc. now owns 1,874,364 shares of the biopharmaceutical company’s stock valued at $10,946,000 after acquiring an additional 256,441 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Aratana Therapeutics by 8.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,491,196 shares of the biopharmaceutical company’s stock worth $8,709,000 after buying an additional 114,998 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Aratana Therapeutics by 22.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,118,836 shares of the biopharmaceutical company’s stock worth $6,534,000 after buying an additional 208,508 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Shares of NASDAQ PETX traded down $0.06 during mid-day trading on Wednesday, reaching $4.05. 480,109 shares of the company were exchanged, compared to its average volume of 798,449. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70. The stock has a market capitalization of $199.34 million, a P/E ratio of -4.18 and a beta of 1.45. Aratana Therapeutics Inc has a 1 year low of $3.67 and a 1 year high of $7.16.

A number of equities analysts have recently issued reports on the company. William Blair downgraded Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 price target on the stock. in a research report on Thursday, January 24th. Stifel Nicolaus downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $8.00 to $5.00 in a research report on Friday, January 11th. BidaskClub downgraded Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 11th. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Wednesday, January 2nd. Finally, TheStreet raised Aratana Therapeutics from a “d” rating to a “c-” rating in a research report on Wednesday, November 21st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $6.94.

In related news, insider Peter Steven St sold 46,094 shares of the company’s stock in a transaction on Monday, December 17th. The stock was sold at an average price of $5.85, for a total transaction of $269,649.90. Following the completion of the sale, the insider now directly owns 516,626 shares in the company, valued at approximately $3,022,262.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aratana Therapeutics Inc (NASDAQ:PETX) Shares Bought by Vanguard Group Inc” was first published by Fairfield Current and is the property of of Fairfield Current. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.fairfieldcurrent.com/news/2019/02/27/aratana-therapeutics-inc-petx-position-lifted-by-vanguard-group-inc.html.

Aratana Therapeutics Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Story: What is a capital gain?

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aratana Therapeutics Inc (NASDAQ:PETX) Insider John C. Ayres Sold 3125 Shares

Finally, Two Sigma Investments LP lifted its position in shares of Aratana Therapeutics by 314.9% during the 4th quarter. Two Sigma Investments LP …

Aratana Therapeutics Inc (NASDAQ:PETX) insider John C. Ayres sold 3,125 shares of the company’s stock in a transaction that occurred on Wednesday, January 30th. The shares were sold at an average price of $4.19, for a total value of $13,093.75. Following the sale, the insider now owns 129,889 shares in the company, valued at approximately $544,234.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of PETX stock opened at $4.42 on Monday. Aratana Therapeutics Inc has a 12-month low of $3.67 and a 12-month high of $7.16. The company has a market capitalization of $211.50 million, a P/E ratio of -4.56 and a beta of 1.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC boosted its stake in Aratana Therapeutics by 116.7% during the 4th quarter. Millennium Management LLC now owns 642,923 shares of the biopharmaceutical company’s stock valued at $3,941,000 after purchasing an additional 346,243 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Aratana Therapeutics by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 17,040 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 13,308 shares in the last quarter. Impax Asset Management Group plc acquired a new stake in shares of Aratana Therapeutics during the 4th quarter valued at $221,000. Bank of America Corp DE lifted its position in shares of Aratana Therapeutics by 21.5% during the 4th quarter. Bank of America Corp DE now owns 38,391 shares of the biopharmaceutical company’s stock valued at $236,000 after acquiring an additional 6,803 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Aratana Therapeutics by 314.9% during the 4th quarter. Two Sigma Investments LP now owns 44,008 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 33,400 shares during the last quarter. 68.23% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have recently weighed in on PETX. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 8th. BidaskClub upgraded Aratana Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 8th. TheStreet upgraded Aratana Therapeutics from a “d” rating to a “c-” rating in a research report on Wednesday, November 21st. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 5th. Finally, ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $6.94.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: Determine Your Level of Risk Tolerance

Related Posts:

  • No Related Posts

Aratana Therapeutics Inc (PETX) Position Lifted by Vanguard Group Inc

Vanguard Group Inc increased its holdings in shares of Aratana Therapeutics Inc (NASDAQ:PETX) by 3.8% during the third quarter, according to its …

Aratana Therapeutics logoVanguard Group Inc increased its holdings in shares of Aratana Therapeutics Inc (NASDAQ:PETX) by 3.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,044,208 shares of the biopharmaceutical company’s stock after acquiring an additional 75,166 shares during the period. Vanguard Group Inc owned approximately 4.20% of Aratana Therapeutics worth $11,938,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics during the third quarter worth $215,000. Bank of Montreal Can grew its holdings in Aratana Therapeutics by 152.9% in the third quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 31,053 shares during the last quarter. Acadian Asset Management LLC grew its holdings in Aratana Therapeutics by 69.8% in the third quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock valued at $1,137,000 after purchasing an additional 80,064 shares during the last quarter. Northern Trust Corp grew its holdings in Aratana Therapeutics by 7.2% in the second quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock valued at $2,082,000 after purchasing an additional 32,773 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Aratana Therapeutics by 16.0% in the second quarter. Dimensional Fund Advisors LP now owns 910,328 shares of the biopharmaceutical company’s stock valued at $3,869,000 after purchasing an additional 125,232 shares during the last quarter. 67.87% of the stock is currently owned by hedge funds and other institutional investors.

PETX opened at $4.39 on Tuesday. The company has a current ratio of 3.17, a quick ratio of 2.70 and a debt-to-equity ratio of 0.02. The firm has a market cap of $213.44 million, a P/E ratio of -4.53 and a beta of 1.45. Aratana Therapeutics Inc has a 52 week low of $3.67 and a 52 week high of $7.16.

Several analysts have weighed in on PETX shares. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 target price on the stock in a report on Wednesday, January 2nd. BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 17th. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and lowered their target price for the company from $8.00 to $5.00 in a report on Friday, January 11th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 22nd. Finally, William Blair lowered Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 target price on the stock. in a report on Thursday, January 24th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Aratana Therapeutics currently has an average rating of “Buy” and an average price target of $6.94.

In related news, insider Peter Steven St sold 46,094 shares of the stock in a transaction on Monday, December 17th. The stock was sold at an average price of $5.85, for a total transaction of $269,649.90. Following the sale, the insider now owns 516,626 shares of the company’s stock, valued at $3,022,262.10. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Ernst Heinen sold 19,308 shares of the stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total value of $134,190.60. Following the sale, the insider now directly owns 135,694 shares in the company, valued at approximately $943,073.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,527 shares of company stock worth $416,934. Corporate insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aratana Therapeutics Inc (PETX) Position Lifted by Vanguard Group Inc” was first published by Fairfield Current and is owned by of Fairfield Current. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/02/05/aratana-therapeutics-inc-petx-position-lifted-by-vanguard-group-inc.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: Blue-Chip Stocks

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aratana Therapeutics Inc (PETX) Holdings Cut by Renaissance Technologies LLC

Renaissance Technologies LLC reduced its stake in shares of Aratana Therapeutics Inc (NASDAQ:PETX) by 30.8% in the 3rd quarter, according to its …

Aratana Therapeutics logoRenaissance Technologies LLC reduced its stake in shares of Aratana Therapeutics Inc (NASDAQ:PETX) by 30.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 264,100 shares of the biopharmaceutical company’s stock after selling 117,300 shares during the quarter. Renaissance Technologies LLC owned 0.54% of Aratana Therapeutics worth $1,542,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in PETX. BlackRock Inc. raised its stake in Aratana Therapeutics by 11.5% during the second quarter. BlackRock Inc. now owns 3,348,240 shares of the biopharmaceutical company’s stock worth $14,231,000 after acquiring an additional 345,204 shares in the last quarter. General American Investors Co. Inc. grew its holdings in shares of Aratana Therapeutics by 15.9% during the third quarter. General American Investors Co. Inc. now owns 1,874,364 shares of the biopharmaceutical company’s stock worth $10,946,000 after purchasing an additional 256,441 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Aratana Therapeutics by 22.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,118,836 shares of the biopharmaceutical company’s stock worth $6,534,000 after purchasing an additional 208,508 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Aratana Therapeutics by 8.4% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,491,196 shares of the biopharmaceutical company’s stock worth $8,709,000 after purchasing an additional 114,998 shares during the last quarter. Finally, Acadian Asset Management LLC grew its holdings in shares of Aratana Therapeutics by 69.8% during the third quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after purchasing an additional 80,064 shares during the last quarter. Hedge funds and other institutional investors own 67.95% of the company’s stock.

Several analysts have recently commented on PETX shares. BidaskClub cut Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research cut Aratana Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 5th. Finally, TheStreet raised Aratana Therapeutics from a “d” rating to a “c-” rating in a research report on Wednesday, November 21st. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $6.94.

In other Aratana Therapeutics news, insider Peter Steven St sold 46,094 shares of the business’s stock in a transaction that occurred on Monday, December 17th. The stock was sold at an average price of $5.85, for a total transaction of $269,649.90. Following the transaction, the insider now owns 516,626 shares of the company’s stock, valued at approximately $3,022,262.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now directly owns 135,694 shares in the company, valued at approximately $943,073.30. The disclosure for this sale can be found here. Insiders have sold a total of 66,094 shares of company stock worth $408,650 in the last ninety days. Insiders own 5.30% of the company’s stock.

Shares of Aratana Therapeutics stock opened at $4.20 on Tuesday. Aratana Therapeutics Inc has a 52-week low of $3.67 and a 52-week high of $7.16. The company has a market capitalization of $205.19 million, a P/E ratio of -4.33 and a beta of 1.78. The company has a current ratio of 3.17, a quick ratio of 2.70 and a debt-to-equity ratio of 0.02.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.03. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. The business had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Research analysts forecast that Aratana Therapeutics Inc will post -0.25 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by Modern Readers and is the property of of Modern Readers. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.modernreaders.com/news/2019/01/29/aratana-therapeutics-inc-petx-holdings-cut-by-renaissance-technologies-llc.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Story: Federal Reserve

Institutional Ownership by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Aratana Therapeutics (PETX) Stock Price Down 26.6%

Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now …

Aratana Therapeutics logoShares of Aratana Therapeutics Inc (NASDAQ:PETX) were down 26.6% during mid-day trading on Friday . The company traded as low as $4.11 and last traded at $4.37. Approximately 6,797,889 shares changed hands during mid-day trading, an increase of 411% from the average daily volume of 1,329,749 shares. The stock had previously closed at $5.95.

A number of analysts have issued reports on PETX shares. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, January 2nd. BidaskClub lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 17th. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 22nd. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $8.00 to $5.00 in a research note on Friday. Finally, HC Wainwright set a $10.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $7.50.

The company has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $21.56 million for the quarter, compared to analyst estimates of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. Research analysts predict that Aratana Therapeutics Inc will post -0.25 EPS for the current year.

In other news, insider Ernst Heinen sold 19,308 shares of Aratana Therapeutics stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now directly owns 135,694 shares of the company’s stock, valued at approximately $943,073.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Peter Steven St sold 11,513 shares of Aratana Therapeutics stock in a transaction dated Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the transaction, the insider now directly owns 562,720 shares in the company, valued at $3,297,539.20. The disclosure for this sale can be found here. Insiders sold a total of 77,607 shares of company stock worth $476,116 over the last ninety days. Corporate insiders own 5.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hollencrest Capital Management acquired a new position in shares of Aratana Therapeutics in the 4th quarter valued at about $153,000. MetLife Investment Advisors LLC acquired a new position in Aratana Therapeutics during the 3rd quarter worth approximately $215,000. Bank of Montreal Can lifted its position in Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 31,053 shares in the last quarter. Acadian Asset Management LLC lifted its position in Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 80,064 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock worth $2,082,000 after acquiring an additional 32,773 shares in the last quarter. 67.92% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Aratana Therapeutics (PETX) Stock Price Down 26.6%” was first published by Fairfield Current and is the property of of Fairfield Current. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.fairfieldcurrent.com/news/2019/01/13/aratana-therapeutics-petx-stock-price-down-26-6.html.

Aratana Therapeutics Company Profile (NASDAQ:PETX)

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

See Also: How is a Moving Average Calculated?

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts